Trimetazidine has been treated as a drug with a high safety and tolerability profile.

Both of these trials also demonstrated the continued manageable safety and tolerability profile of mipomersen.

Within one review prulifloxacin was stated to have a similar tolerability profile to that of ciprofloxacin.

As gefitinib is a selective chemotherapeutic agent, its tolerability profile is better than previous cytotoxic agents.

Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine.

In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile.

Rather, differences among compounds usually relate to dosing regimens (related to the compound's elimination half-life), route of administration, and tolerability profile.

It is commonly used with children and adolescents on account of its favorable safety and tolerability profile and lack of abuse potential.

In pooled analyses, the tolerability profile of sugammadex was generally similar to that of placebo or neostigmine plus glycopyrrolate.

Both Phase II studies indicated a tolerability profile for Solabegron that was similar to placebo.